SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against PolarityTE, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Back to Newsroom
Mentioned in this Article

SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against PolarityTE, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Monday, November 8, 2021 8:15 AM
Share this article now
Topic:
Lawsuits
The Schall Law Firm

LOS ANGELES, CA / ACCESSWIRE / November 8, 2021 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against PolarityTE, Inc. ("PolarityTE" or "the Company") (NASDAQ:PTE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company's securities between April 30, 2020 and August 23, 2021, inclusive (the ''Class Period''), are encouraged to contact the firm before November 23, 2021.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. PolarityTE's Investigational New Drug Application for SkinTE failed to provide sufficient information on Chemistry, Manufacturing, and Control (CMC) items. Based on this deficiency, the FDA was unlikely to approve SkinTE based on the New Drug Application. The Company materially overstated the likelihood of SkinTE achieving regulatory approval. Based on these facts, the Company's public statements throughout the class period were false and materially misleading. When the market learned the truth about PolarityTE, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]

SOURCE: The Schall Law Firm

Back to Newsroom
Copyright 2021 © ACCESSWIRE. All rights reserved. Privacy Policy  |   Terms and Conditions